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Endoscopy remains the most important diagnostic and monitoring modality in the management of inﬂammatory bowel disease.
Advances in imaging have progressively added new tools into the armamentarium of endoscopists with the goal of more
accurate, sensitive, and accessible visual diagnoses for the beneﬁt of patients with gastrointestinal diseases. Here, we review the
relevant literature regarding commonly used endoscopic techniques (dye-based and digital chromoendoscopy, high-deﬁnition
endoscopy, capsule endoscopy, and endosonography), as well as advanced and experimental technologies (full-spectrum
endoscopy, endocytoscopy, autoﬂuorescence, laser endoscopy, and endomicroscopy, including molecular imaging), applicable to
inﬂammatory bowel diseases and emerging for implementation into everyday practice. Additionally, we discuss future directions
and techniques as candidates for a superior inﬂammation imaging in the diagnosis and prediction of therapeutic response.
1. Introduction
Patients with inﬂammatory bowel disease (IBD), comprising
ulcerative colitis (UC), and Crohn’s disease (CD) need regu-
lar endoscopic evaluation for the assessment and monitoring
of the extent and severity of inﬂammation, therapeutic
response, and surveillance for colorectal carcinoma (CRC)
[1]. Currently, a multitude of endoscopic imaging techniques
fulﬁl these necessities based on guideline recommendations.
In addition to standard techniques like high-deﬁnition
white light endoscopy (HD-WLE), emerging experimental
techniques like confocal laser endomicroscopy (CLE) and
multiphoton imaging enrich the endoscopic toolbox pro-
viding vivid and high-resolution images in real time. Indi-
vidual improvements in adenoma detection rates are
pivotal for adoption and implementation of new tech-
niques. In this regard, the awareness of interval cancer in
IBD [2] must increase the eﬃciency of surveillance endos-
copies in IBD patients and focus on higher proﬁciency in
learning and implementing novel endoscopic technologies
in the clinical routine.
The aim of this review is to highlight the current technol-
ogies available for conventional as well as advanced endo-
scopic imaging, both for assessment of inﬂammation and
for neoplasia detection in IBD.
2. Current Recommendations
Screening colonoscopy and therapeutic polypectomy sig-
niﬁcantly reduce the risk of colorectal carcinoma [3].
The widest endoscopic management strategy of CRC
screening in IBD relied initially on the random biopsy
technique published by the American Gastroenterology
Association in 2010 [4]. A 2013 European guideline
regarding IBD screening and surveillance management
recommended targeted biopsies of macroscopically visible
lesions and 2–4 random biopsies every 10 cm within the
colon [5]. In 2015, an international consensus statement
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(SCENIC) recommended chromoendoscopy (CE) as the
preferred endoscopic technique for dysplasia detection
and surveillance [6] in IBD, which is the current standard.
National society guidelines, like those of the British Society
for Gastroenterology (BSG, 2010), also advocate dye pan-
chromoendoscopy with targeted biopsy as the technique
of choice and not virtual CE like NBI. If dye-CE is not
available, the BSG suggests the old recommendation of
2–4 biopsies every 10 cm of the colon and rectum [7]. In
the present high-deﬁnition and targeted technology era,
the standard in endoscopic practice in referral centers
shifted in the last years towards the virtual/digital chro-
moendoscopy. In this regard, if a chromoendoscopic eval-
uation (dye/virtual) with biopsy of the inﬂamed segments
is not possible/not available, a targeted high-deﬁnition
white light endoscopy is to be evaluated as a superior
alternative to the random biopsies. If any of the chromoen-
doscopic techniques (dye or virtual) or high-deﬁnition
endoscopy are not available, then the patient should be han-
dled according to the BSG recommendation, as minimum
standard. If multiple biopsies have to be avoided because of
bleeding complication/anticoagulants and so on, a prodi-
gious standard deﬁnition assessment remains as last option
(with biopsies from any polypoid structure or suspect surface
deformity or inhomogenicity other than classical pseudopo-
lyps) in the case of very high conﬁdence and experience.
Alternatively, the patient should be referred to an endoscopic
unit with an appropriate chromoendoscopy of HD technol-
ogy for a second endoscopic evaluation.
3. Commonly Used Endoscopic
Imaging Techniques
3.1. High-Deﬁnition White Light Endoscopy. High-deﬁnition
white light endoscopy (HD-WLE, Figures 1(c) and 1(e)–
1(g)) was introduced in 1993 and is the current standard in
gastrointestinal endoscopic practice that replaced standard-
deﬁnition video endoscopy (Figures 1(a) and 1(b)). HD-
WLE allows a resolution of more than 1 million pixels per
image and can be visualized on a HD screen. HD-WLE
increases the adenoma detection rate compared to standard
deﬁnition [8] in the general population.
3.2. Chromoendoscopy (CE). Chromoendoscopy (CE) is the
most widespread imaging technique for IBD screening and
is anchored in the latest international guideline (SCENIC)
[6]. CE in the colon comprises dye-based chromoendoscopy
(methylene blue and indigo carmine) and digital chromoen-
doscopy (optical and virtual CE).
3.2.1. Dye-Based CE. Dye-based CE permits characterization
of mucosal lesions by topical stain application. One of the
ﬁrst descriptive methylene blue-aided CE studies was done
in ulcerative proctitis in 1979 by Baldi and co-workers [9].
A good correlation of UC inﬂammation severity in CE
with topical methylene blue and indigo carmine compared
to conventional histology was shown in 25 UC patients by
Ibarra-Palomino et al. [10]. Beyond the standard white
light endoscopy (WLE), studies using dye-based CE with
magniﬁcation endoscopes (cresyl violet plus zooming)
proved a lower clinical and histologic inﬂammation in UC
patients having cryptal openings and a network pattern
[11]. The ﬁrst large study comparing methylene blue-based
CE-targeted biopsies versus WLE with random biopsies was
published by Kiesslich and co-workers proving a superiority
of CE in neoplasia detection [12]—a conclusion later con-
ﬁrmed by other studies using indigo carmine CE [13]. Further
prospective studies have underlined the superiority of CE in
comparison to standard-deﬁnition endoscopy for adenoma
detection both in IBD and in the general population [14–16].
3.2.2. Dye-Less Digital Chromoendoscopy. Dye-less digital
chromoendoscopy uses artiﬁcially staining techniques which
add colour by pressing a button and subsequently enhancing
the mucosal contrast. This is performed either through
optical ﬁlters, so-called optical chromoendoscopy, like the
narrow-band imaging technique (NBI, Olympus, Japan;
Figure 1(h)) [17, 18] or by virtual video postprocessing in real
time, so-called virtual chromoendoscopy (i-Scan, PENTAX,
and FICE, Fujinon, Japan; Figure 1(d)) [19].
Concerning virtual chromoendoscopy, Hofmann and
collaborators compared conventional HD-WLE with i-Scan
and classical CE (with methylene blue) in neoplasia detec-
tion. In this setting, i-Scan imaging proved equal to methy-
lene blue-aided CE in identifying neoplastic lesions [20].
Furthermore, neoplasia detection using colonoscopy with i-
Scan was superior to standard colonoscopy [21]. i-Scan
imaging in comparison to histology results also provided a
more precise assessment of inﬂammation in IBD patients
[22]. This fact allows a targeted bioptic sampling from
pathological mucosal areas for disease conﬁrmation by his-
tology. In other publications, the Erlangen group described
the utility of virtual chromoendoscopy with i-Scan for the
real-time diagnosis of both gastric and duodenal CD [23, 24].
Using this technique, irregular thickened folds in the duode-
num, reddish areas, and especially CD-typical aphthoid
erosions were characterized, which were not evident on con-
ventional HD-WLE imaging [23]. In the stomach, i-Scan
imaging revealed erythematous CD-associated inﬂammatory
areas and spots as well as aphthoid lesions [24]. These virtual
CE ﬁndings may facilitate an earlier diagnosis of upper gas-
trointestinal CD and allow targeted biopsies for histological
conﬁrmation [23, 24]. Similar ﬁndings have been reported
in the colon [25].
A very recent comparative study of Iacucci and co-
workers proved that i-Scan or HD-WLE is not inferior to
dye spraying chromocolonoscopy for detection of colonic
neoplastic lesions during surveillance colonoscopy [26].
Regarding optical chromoendoscopy, NBI colonoscopy
has been shown to be more precise in diagnosing the degree
of inﬂammation in patients with quiescent UC, when
compared with conventional HD-WLE [27]. Furthermore,
Kudo and co-workers proved a more precise grading of
the inﬂammatory activity in UC with NBI [27] compared
to histopathology (as gold standard). NBI colonoscopy
was demonstrated to be a useful tool for the in vivo detec-
tion of angiogenesis in IBD, with a signiﬁcant increase in
vessel density in inﬂamed areas, which were NBI-positive
2 Gastroenterology Research and Practice
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 1: Endoscopic images depicting Crohn’s disease (CD) and ulcerative colitis (UC) lesions with diﬀerent techniques and resolutions:
image (a) shows a moderate to severe Crohn’s colitis, while (b) shows a mild UC (endoscopic Mayo 1), both in standard deﬁnition.
Images (c) and (d) depict again a distal UC involvement in high-deﬁnition white light (HD-WLE) as well as in digital chromoendoscopy
using i-Scan (Mayo 1–2). In comparison, pictures (e) and (f) show a severe CD of the ileum and colon (high-deﬁnition WLE and i-Scan).
Images (g) and (h) show high-deﬁnition WLE and narrow-band imaging (NBI) (h) of a gastric CD, highlighting erosions and
aphthoid lesions.
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[28]. In one case report, NBI colonoscopy was used to
detect a DALM (dysplasia-associated lesion or mass) in a
UC patient [29]. In a ﬁrst prospective study where NBI
colonoscopy was compared with conventional colonoscopy
for the detection of dysplasia in patients with long-standing
UC, the sensitivity of the (ﬁrst generation) NBI system for
neoplasia detection was similar to conventional colonoscopy,
although more suspicious lesions were found during NBI
[30]. Matsumoto and co-workers went further and demon-
strated the value of magniﬁcation imaging with NBI for neo-
plasia prediction in UC [31]. Another study showed that NBI
required less biopsy sampling and a shorter withdrawal time
in comparison to WLE in neoplasia detection in UC patients
[32]. In contrast, a recent study showed that NBI did not
improve the detection of neoplasia in patients with UC com-
pared to HD-WLE. Therefore, NBI proved unsatisfactory for
diﬀerentiating neoplastic from nonneoplastic mucosa [33].
In a crossover study of 29 patients with IBD, Sussman and
co-workers compared WLE, dye-based CE (indigo carmine),
and NBI [34]. Hereby, WLE and CE accuracy showed supe-
riority over NBI (64% and 63% versus 42%, resp.) in inﬂam-
mation and pseudopolyp histology prediction.
A recent noninferiority crossover trial utilized WLE,
dye-based CE (methylene blue), and i-Scan imaging during
surveillance colonoscopy [35]. In this paper, Iacucci and
co-workers showed a beneﬁt of applying CE imaging in
the detection and characterization of sessile serrated ade-
nomas in IBD surveillance colonoscopies (93% sensitivity
and speciﬁcity).
In a randomized trial comparing CE versus NBI, there
was no signiﬁcant diﬀerence in the detection of colitis-
associated neoplasia, although the total procedural time was
on average 7min shorter in the NBI group [36].
Data regarding virtual CE with FICE (Fujinon intelligent
chromoendoscopy) technology in IBD are currently lacking.
3.2.3. Limitations. Although CE is easily applicable and ready
available (push of a button on the endoscopic tip or topical
dye application), there are still technologic diﬀerences in
the equipment standards between endoscopy centers, espe-
cially because of high acquisition cost for HD/HD+devices.
Another limitation is the lack of standardized training, as
well as a lack of standardized diagnostic and staging scores
applicable to the diﬀerent techniques.
3.3. Endoscopic Ultrasound. Although endoscopic ultrasound
(EUS) has an established role in conventional gastrointestinal
imaging, in IBD it is not widely used. EUS is capable of
providing parietal (intramural) as well as transmural and
extraluminal imaging, as additional data to conventional
transabdominal ultrasound. During the diagnosis and stag-
ing of IBD, characterization of the intestinal layers may be
important in uncertain cases to diﬀerentiate between UC
and CD. Rectal ultrasound is sometimes useful for assess-
ment of IBD severity and for perianal ﬁstula and abscess
characterization, utilizing rigid rectal ultrasound probes
[37]. Modern echo-endoscopes permit deeper EUS data
acquisition beyond the sigmoid colon to assess mucosal and
submucosal as well as total wall thickness and locoregional
lymph nodes. In a blinded study of 52 patients, EUS was
able to diﬀerentiate UC from CD and wall thickness corre-
lated well with activity and histology [38]. When mucosal-
submucosal and total wall thickness and lymph node
detection were combined, the sensitivity was 92.3% for
the diﬀerentiation of active UC/CD. Further, there was a
strong correlation of total wall thickness with histological
inﬂammation scores.
3.3.1. Limitations. EUS deﬁnes more precisely transmural
pathology and is not applicable in UC. Although it has high
sensitivity, EUS is rarely used in routine IBD diagnostics.
3.4. Capsule Endoscopy. For diagnosing indeterminate IBD
cases, for description of location and extent of inﬂammation
in CD, and ﬁnally for therapeutic monitoring, capsule endos-
copy has proved feasible and informative, especially in cases
where bidirectional conventional endoscopy and entero-
scopy were inconclusive or not (easily) applicable (like in
paediatric adverse events [39]). Before capsule usage, radio-
logic exclusion of a signiﬁcant bowel stenosis is mandatory
(risk of hang-up and subsequent need for surgery). The
ﬁrst capsule endoscopy experience in IBD was published
in 2004 [40]. In a large single-center study [41], capsule
endoscopy ﬁndings led to changes in the management of
the majority of IBD patients. Hereby, capsule endoscopy
ﬁndings in 128 investigations over 6 years consisted of
aphthae/ulcers (22.1%), stenosis (8.1%), and stenosis with
capsule retention (17.4%). 61.6% of CD patients had a
subsequent change in medication within 3 months after
capsule endoscopy, as 39.5% initiated new IBD medica-
tion. Following capsule endoscopy, 12.8% of CD patients
needed surgery within 3 months. Severe ﬁndings on capsule
endoscopy in CD patients, as compared to no/minimal
ﬁndings, resulted in signiﬁcant diﬀerences in medication
changes (73.2% versus 51.1%, P = 0 04), addition of medica-
tions (58.5% versus 22.2%, P < 0 01), and surgeries (21.9%
versus 4.4%, P = 0 01) [41]. Multiple comparative studies
proved the diagnostic yield superiority of 83–100% [42–44]
for capsule endoscopy related to computer and magnetic
resonance tomography, push enteroscopy, and even ileoco-
lonoscopy [45].
3.4.1. Limitations. The limitation of capsule endoscopy rely
in its usefulness strictly in isolated cases of uncertain IBD
and small bowel CD without ileus or radiologically evidenced
stenosis/strictures or intestinal passage disruptions.
4. Advanced Endoscopic Imaging Techniques
4.1. Full-Spectrum Endoscopy (FUSE®). Full-spectrum endos-
copy (FUSE) is a new high-deﬁnition endoscope that incor-
porates supplementary lateral camera lenses (to the right
and left sides of the colonoscope tip) in addition to the stan-
dard forward-viewing camera. These 3 lenses deliver a 330°
panoramic ﬁeld of view of the mucosa as opposed to the
170° ﬁeld of view from a conventional forward-viewing
colonoscope. One study demonstrated an improved visuali-
zation of the side walls, blind spots, and behind folds. The
FUSE system provided a signiﬁcantly decreased adenoma
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miss rate from 41% using forward-viewing colonoscopes (20
adenomas missed a total of 49) to 7% using FUSE (5 adeno-
mas missed of a total of 67) in a tandem back-to-back colo-
noscopy study of a non-IBD population [46]. In a recent
prospective study of IBD patients, panoramic imaging
obtained by FUSE increased the number of dysplastic lesions
detected, compared with conventional forward-viewing colo-
noscopy. Hereby, forward-viewing colonoscopy missed
71.4% of dysplastic lesions per lesion whereas FUSE missed
25.0% per lesion [47]. Still, further multicenter studies are
necessary to conﬁrm these data.
4.2. Endocytoscopy. Endocytoscopy (Olympus, Japan) is
based on the optical principle of contact light microscopy,
delivering in vivo real-time ultra-magnifying microscopic
imaging of the mucosal surface at a magniﬁcation up to
1390-fold [48, 49]. Regarding the diagnostic yield of endocy-
toscopy in UC, Bessho et al. [50] showed in a cohort of 55 UC
patients a correlation of rho = 0 713 (P < 0 001) between
endoscopy and histopathological activity and a κ value of
0.79 in the validation of the proposed endocytoscopy sys-
tem score (ECSS) [50]. Another study regarding the value
of endocytoscopy for describing inﬂammatory activity in
IBD showed a precise discrimination of single mucosal
inﬂammatory cells and also the degree of inﬂammation
[51]. The sensitivities and speciﬁcities for cytologic detection
were neutrophilic (60% and 95%), basophilic (74.43% and
94.44%), and eosinophilic granulocytes (75% and 90.48%)
and lymphocytes (88.89% and 93.33%), while interobserver
and intraobserver agreements were 0.61–0.78 and 0.76–
0.88, respectively. Concordance between EC and histopa-
thology for grading of the intestinal disease activity was
100% [51].
Further prospective studies are needed to extend the
diagnostic possibilities of this method.
4.3. Fluorescence and Autoﬂuorescence Endoscopy. Both ﬂuo-
rescence and autoﬂuorescence endoscopy are emerging
imaging techniques that rely on visualization of ﬂuorescence
light (wavelength: 500–630nm) emitted by either adminis-
tered or endogenous ﬂuorophores. In a prospective study
of 43 patients with UC, the yield of autoﬂuorescence
imaging was superior to WLE in inﬂammation detection
(85% versus 79%) [52]. Fluorescence endoscopy with 5-
aminolevulinic acid (5-ALA) in comparison with WLE
showedno signiﬁcant diﬀerence in the dysplasia detection rate
in IBD [53]. Finally, a crossover trimodal study comparing
autoﬂuorescence imaging with NBI andWLE showed a supe-
riority of autoﬂuorescence in neoplasia detection in UC [54].
Autoﬂuorescence endoscopic studies on IBDandpublications
are rare, which still leave broad possibilities for further
research endeavours.
4.4. Confocal Laser Endomicroscopy in IBD
4.4.1. CLE for Assessment and Characterization of
Inﬂammation and Mucosal Healing Prediction. Confocal
laser endomicroscopy (CLE) is a sophisticated endoscopic
imaging technique introduced in 2004 that allows a so-
called optical biopsy. Two CLE systems are available, the
integrated endoscopic system (eCLE, from PENTAX, Tokyo,
Japan; Figures 2(a) and 2(b)) and the probe-based system
(pCLE, from Mauna Kea Technologies, Paris, France;
Figures 2(c) and 2(d)), the latter being passable through the
working channel of standard endoscopes. By enabling real-
time in vivo visualization of a plethora of novel cellular and
subcellular details, which correlates with conventional histol-
ogy, CLE has the potential to have a major impact on endo-
scopic diagnosis [49, 55, 56]. Due to its resolution and
tissue penetration of approximately 250μm, endomicro-
scopy can describe several aspects of mucosal architecture
like crypt alteration (form, density, integrity, crypt lumen
distortion, crypt leakage, and goblet cell density within
the crypts) as well as microvascular changes (increased
vascularity, vascular integrity, and leakage). Based on these
two important criteria, Li and co-workers described the
ﬁrst CLE classiﬁcation of inﬂammation activity for UC
[57]. Prior to this publication, in 2008, Watanabe and
co-workers described the microscale mucosal changes pro-
vided by CLE between inﬂamed and noninﬂamed colon in
UC [58].
The Erlangen group provided the endomicroscopic
inﬂammation criteria for a Crohn’s colitis activity score
[59]. Furthermore, the gastric and duodenal manifestations
of CD were described and diagnosed in vivo, based on
high-deﬁnition and virtual chromoendoscopy-guided endo-
microscopy (eCLE) [24, 60, 61]. The same group provided
in vivo diﬀerentiation criteria between CD and UC using
CLE [62]. In a prospective study, Kiesslich and co-workers
[63] published data on the utility of eCLE in predicting an
IBD relapse, by describing the process of cell shedding and
quantifying the local epithelia barrier dysfunction. In IBD
patients in clinical remission, the increase in cell shedding
with ﬂuorescein leakage was associated with subsequent
relapse within 12 months [63]. Further recent advances in
IBD diagnosis and outcome assessment have addressed the
capacity of eCLE to evaluate and deﬁne more precisely the
process of mucosal healing during standard therapy (anti-
TNF antibodies) [64]. The Erlangen group prospectively val-
idated the ﬁrst CLE mucosal healing score for colonic
Crohn’s colitis und UC, with high sensitivity and speciﬁcity
values compared with histology (Gupta Index). This score,
designed for everyday use in clinical practice, used eCLE to
predict mucosal healing and therapeutic outcome over a
period of 3 years in UC [64]. IBD patients showing an eMHs
score < 1 had a long-lasting clinical remission and reduced
hospitalization, steroid, and surgery need, which qualiﬁes
the endomicroscopic mucosal healing score and the CLE
implicitly as a valuable tool for prediction of a deep lasting
remission [64].
Another prospective study of CLE focused on developing
an intestinal permeability score in patients with IBD. An
impaired intestinal permeability correlated with ongoing
bowel symptoms, while an increase in permeability corre-
lated with increased severity of diarrhea [65].
The value of CLE in IBD has been recently addressed in
two Danish studies. Karstensen et al. showed that eCLE can
predict a relapse in quiescent CD by highlighting ﬂuores-
cence leakage and microerosions as risk factors for an
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(c) (d)
(e)
Figure 2: Endomicroscopic imaging in Crohn’s disease and ulcerative colitis. Images (a) and (b) show endomicroscopic images provided by
the integrated system (eCLE) with typical inﬂamed crypts and hypervascularization in Crohn’s colitis (a) and ulcerative colitis (b); arrowhead
points towards vascular leakage. Pictograms (c) and (d) show endomicroscopic images provided by the probe-based system (pCLE) in a
Crohn’s disease patient with colonic and ileal involvement (arrowhead in (c) shows a deformed crypt with lumen leakage; arrowhead in
(d) shows a typical epithelial gap). (e) shows a premier molecular endomicroscopic imaging of golimumab FITC (ex vivo eCLE) in an
ulcerative colitis patient that underwent proctocolectomy (arrowhead shows golimumab FITC-positive cells in the lamina propria,
suggesting the high number and density of eﬀector cells of inﬂammation).
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inﬂammatory fallback in 50 IBD patients (P = 0 043 and
P = 0 034, respectively; inter- and intraobserver reproduc-
ibility κ > 0 80 and κ > 0 60, meaning a good agreement)
[66]. The same group described pCLE to assess the longi-
tudinal histologic changes upon various immunosuppres-
sive therapies in UC patients [67]. Prediction of UC
relapse by pCLE, based on crypt structural and microvas-
cular criteria, was conﬁrmed by an Italian group [68].
4.4.2. CLE in Neoplasia Detection and Surveillance in IBD.
Regarding the value of CLE for detection of dysplasia-
associated lesions or mass (DALM) or adenoma-like mass
(ALM) in UC patients, Hurlstone and co-workers obtained
high accuracy values, for example, the agreement between
CLE and histopathologic evaluation was κ = 0 91, and
accuracy was 97% [69]. Indigo carmine-aided pCLE
accurately detected dysplasia in long-standing UC [70].
This study emphasized the advantages of combining imag-
ing techniques to improve diagnostic accuracy. By using
bimodal imaging, Kiesslich and co-workers showed that
targeted eCLE using chromoendoscopy guidance (with
methylene blue) had a signiﬁcantly higher diagnostic yield
(4.75-fold) for neoplasia detection in UC patients, than
conventional colonoscopy with random biopsies [71].
The same work showed that this dual imaging technique
reduced the need for biopsies by 50 percent. On the same
issue of targeted versus random biopsies for neoplasia
detection in IBD, Günther et al. [72] compared random
biopsy during WLE with CE (indigo carmine and quad-
rantic biopsies) and eCLE (with targeted versus random
biopsies). CE- and eCLE-guided targeted biopsies were
more accurate in neoplasia detection in UC than random
biopsies during WLE.
A similar randomized trial with methylene blue CE-
guided eCLE versus WLE with random biopsies in neoplasia
detection in 162 UC patients with high neoplastic risk (as IN,
intraepithelial neoplasia history, or PSC) revealed no signiﬁ-
cant diﬀerence in the detection for IN (8 versus 7 patients)
[73], although the targeted approach did reduce biopsy
sampling, in line with Kiesslich et al.’s study [71].
Comparative studies between colonoscopy with NBI and
pCLE regarding detection yield for IN have also been
addressed [74]. In one study, NBI was superior to pCLE in
neoplastic discrimination of sessile and pedunculated polyps
in UC (sensitivity, speciﬁcity, and accuracy of 100%, 89%,
and 92% versus 65%, 82%, and 81%, resp.), although diﬀerent
approaches were applied (blind pCLE versus real-time NBI
assessment), making objective comparisons diﬃcult.
CD surveillance studies are rarer compared to UC trials.
A recent prospective study from 2016 showed a limited prac-
tical applicability for neoplasia detection in CD by CE-guided
eCLE [75]. CE-guided eCLE presented a low dysplasia detec-
tion rate of IN (9.8%). The combination of CE and eCLE for
diﬀerentiating neoplastic from nonneoplastic lesions had an
accuracy of 86.7%, sensitivity of 42.9%, and speciﬁcity of
92.4%. For CE alone, this was 80.3% (95% CI, 70.7–89.9),
28.6% (95% CI, 5.1–69.7), and 86.4% (95% CI, 80.9–97.6).
There are only a few studies addressing molecular imag-
ing in IBD using the CLE technique (Figure 2(e)). In a
prospective study of 25 patients with CD, the Erlangen group
described the feasibility of topically administered ﬂuores-
cein isothiocyanate- (FITC-) conjugated adalimumab to
detect intestinal membrane-bound tumour necrosis factor-
(mTNF-) positive immune cells. Patients with high num-
bers of mTNF(+) cells had signiﬁcantly higher short-term
response rates to anti-TNF therapy, which was sustained
over a 1-year follow-up period [76].
Although the CLE enthusiasm of the pioneering years
decreased, confocal technology remains a promising tool
for real-time cellular diagnosis, mucosal healing prediction
[64], and molecular imaging, but reforms regarding reim-
bursements as well as lower acquisition cost have to promote
a broader implementation of CLE from study settings into
real-life daily routine.
4.4.3. CLE Limitations. Despite the potential of this tech-
nique, CLE has limitations including costs issues (inadequate
reimbursement in Europe, expensive acquisition) and limited
accessibility since it is available only in large, mostly aca-
demic endoscopy centers. One of the apparent limitations
of the eCLE both in multicenter studies [75] and single-
center experience [50] were dysfunctions of the laser unit
(of the eCLE system). Another limitation in most CLE stud-
ies, with pCLE and eCLE, is an unavoidable bias in the collec-
tion of CLE data, inﬂuenced by the surface pattern seen on
conventional endoscopy. This limitation is unavoidable,
and a blinded CLE sampling is impossible because the CLE
technique in itself represents a point technique that needs
direct and targeted contact with the mucosal area of interest.
Here, the CLE sampling has to be done in areas of the color-
ectumwith representative ﬁndings (e.g., inﬂammation), since
a complete CLE investigation of the entire colon and rectum
is impossible. In this regard, the general limitation of sam-
pling error has to be underlined, since the technique allows
only the analysis of a very small mucosal area compared to
the real surface extent of diseases like IBD. Further, CLE
imaging as supplementary acquisition method requires extra
time, which logically extends the entire investigation time
and needs higher sedation need.
5. Conclusions and Perspectives
An increased number of diagnostic and surveillance imaging
novelties like multiband confocal imaging or multimodal
studies that combine more than two advanced endoscopic
imaging techniques will most probably bring in the future
new insights for better diagnosis and management of the
two IBD entities, CD and UC. Before more widespread adop-
tion of these techniques, speciﬁc limitations of the describe
techniques must also be addressed, including limited avail-
ability because of high acquisition costs and insuﬃcient
reimbursement, lack of standardized training and diagnostic
scores, and the additional time necessary for investigation.
Better reimbursement rates are needed in order to translate
techniques like CLE from the experimental levels into the
wide daily practice.
In the near future, techniques like the dual-band or
multiband endomicroscopy will enrich the endoscopic
7Gastroenterology Research and Practice
armamentarium, allowing the usage of 2 ﬂuorophores and
more complex molecular imaging. Further, technical devel-
opments with slimmer and more ﬂexible endoscopes, as well
as improvements in digital optics like three-dimensional
endoscopy and ultra-high-deﬁnition imaging (UHD/4K),
are expected to enter into endoscopic production.
In conclusion, a targeted approach combining several
imaging technologies in IBD diagnosis brings advantages
regarding accuracy and reduces the necessity of classical for-
ceps biopsy, as well as overall risks, which should encourage
the adoption, implementation, and standardization of these
modern techniques into clinical practice.
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